SR-31742A
 | |
| Clinical data | |
|---|---|
| Other names | SR31742A; SR-31742; SR31742 |
| Routes of administration | Unknown[1] |
| Drug class | Sigma receptor modulator |
| ATC code |
|
| Identifiers | |
| |
| CAS Number |
|
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C21H30ClN |
| Molar mass | 331.93 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
SR-31742A, or SR-31742, is a sigma receptor modulator which was under development for the treatment of schizophrenia and manic episodes but was never marketed.[1][2][3][4][5] Its route of administration is unknown.[1]
The drug is selective for the sigma receptors and shows high affinity for 3-PPP-labeled sigma receptors (Ki = 5.3 nM).[3] Its selectivity for the sigma σ1 versus σ2 receptor is unknown, though it is known to have high affinity for the sigma σ1 receptor specifically.[4] Whether SR-31742A is an agonist or antagonist of the sigma σ1 receptor is said to be unknown,[4] though it has been described as an antagonist in some publications.[5] The drug reduces the hyperlocomotion induced by dextroamphetamine and various other drugs without affecting spontaneous locomotor activity in rodents.[4][3]
SR-31742A was under development by Sanofi-Synthelabo.[1][2] It reached phase 2 clinical trials for both schizophrenia and manic episodes prior to the discontinuation of its development in 2001.[1][2]
See also
[edit]References
[edit]- 1 2 3 4 5 "SR 31742A". AdisInsight. 9 March 2001. Retrieved 5 June 2026.
- 1 2 3 "Delving into the Latest Updates on SR-31742A with Synapse". Synapse. 30 May 2026. Retrieved 5 June 2026.
- 1 2 3 Poncelet M, Santucci V, Paul R, Gueudet C, Lavastre S, Guitard J, et al. (June 1993). "Neuropharmacological profile of a novel and selective ligand of the sigma site: SR 31742A". Neuropharmacology. 32 (6): 605–615. doi:10.1016/0028-3908(93)90057-a. PMID 8336824.
- 1 2 3 4 Cobos EJ, Entrena JM, Nieto FR, Cendán CM, Del Pozo E (December 2008). "Pharmacology and therapeutic potential of sigma(1) receptor ligands". Current Neuropharmacology. 6 (4): 344–366. doi:10.2174/157015908787386113. PMC 2701284. PMID 19587856.
- 1 2 Ujike H, Kuroda S, Otsuki S (January 1996). "sigma Receptor antagonists block the development of sensitization to cocaine". European Journal of Pharmacology. 296 (2): 123–128. doi:10.1016/0014-2999(95)00693-1. PMID 8838447.
